All Stories

  1. Treatment of classical Hodgkin’s lymphoma in children and adolescents

    Article • Expert Opinion on Pharmacotherapy, April 2019, Taylor & Francis

    Dr David Gomez-Almaguer

  2. Clinical presentation in thrombotic thrombocytopenic purpura: Real-world data from two Mexican institutions

    Article • Journal of Clinical Apheresis, October 2018, Wiley

    Professor Guillermo Jose Ruiz-Arguelles, Dr David Gomez-Almaguer, José C Jaime-Pérez

  3. Eltrombopag-based combination treatment for immune thrombocytopenia

    Article • Therapeutic Advances in Hematology, October 2018, SAGE Publications

    Dr David Gomez-Almaguer

  4. Evans syndrome: clinical perspectives, biological insights and treatment modalities

    Article • Journal of Blood Medicine, October 2018, Dove Medical Press

    José C Jaime-Pérez, Dr David Gomez-Almaguer

  5. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico

    Article • Cancer, February 2018, Wiley

    Dr David Gomez-Almaguer, José C Jaime-Pérez

  6. Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia

    Article • British Journal of Haematology, December 2017, Wiley

    Dr David Gomez-Almaguer, José C Jaime-Pérez

  7. Comparison of conventional cytomorphology, flow cytometry immunophenotyping, and automated cell counting of CSF for detection of CNS involvement in acute lymphoblastic leukemia

    Article • International Journal of Laboratory Hematology, November 2017, Wiley

    Dr David Gomez-Almaguer, José C Jaime-Pérez, Rosario Salazar Riojas

  8. The effect of intra-articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis

    Article • International Journal of Rheumatic Diseases, July 2017, Wiley

    Dr David Gomez-Almaguer, José C Jaime-Pérez

  9. Hospitalization rate and costs in acute lymphoblastic leukemia of childhood in a low-income group: Financial impact in Northeast Mexico

    Article • Pediatric Blood & Cancer, June 2017, Wiley

    Dr David Gomez-Almaguer, José C Jaime-Pérez

  10. Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor

    Article • Hematology, June 2017, Taylor & Francis

    José C Jaime-Pérez, Dr David Gomez-Almaguer

  11. Haploidentical Bone Marrow Transplantation in 2015 and Beyond

    Article • Current Oncology Reports, October 2015, Springer Science + Business Media

    Dr David Gomez-Almaguer

  12. Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2015, Elsevier

    Dr David Gomez-Almaguer

  13. Some observations on the publication of articles in Medicine

    Article • Medicina Universitaria, September 2015, Elsevier

    Dr David Gomez-Almaguer

  14. Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma

    Article • Archives of Medical Research, August 2015, Elsevier

    Dr David Gomez-Almaguer

  15. Experience with Evans syndrome in an academic referral center

    Article • Revista Brasileira de Hematologia e Hemoterapia, July 2015, Elsevier

    Dr David Gomez-Almaguer

  16. Impact of outpatient non-myeloablative haematopoietic stem cell transplantation in quality of life vs. conventional therapy

    Article • Psychology Health & Medicine, June 2015, Taylor & Francis

    Dr David Gomez-Almaguer

  17. Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia

    Article • Cancer Biomarkers, June 2015, IOS Press

    Dr David Gomez-Almaguer

  18. Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation

    Article • Bone Marrow Transplantation, May 2015, Nature

    Dr David Gomez-Almaguer

  19. Evaluation of hemoglobin performance in the assessment of iron stores in feto-maternal pairs in a high-risk population: receiver operating characteristic curve analysis

    Article • Revista Brasileira de Hematologia e Hemoterapia, May 2015, Elsevier

    Dr David Gomez-Almaguer

  20. Human communication, the internet, medicine and its addictions

    Article • Medicina Universitaria, April 2015, Elsevier

    Dr David Gomez-Almaguer

  21. No clinically relevant differences between capillary and venous blood cell counts in adult haematological patients using a nonautomated lancet

    Article • International Journal of Laboratory Hematology, March 2015, Wiley

    Dr David Gomez-Almaguer

  22. Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico

    Article • The Oncologist, March 2015, Alphamed Press

    Dr David Gomez-Almaguer

  23. Increased Bacterial Infections after Transfusion of Leukoreduced Non-Irradiated Blood Products in Recipients of Allogeneic Stem Cell Transplants after Reduced-Intensity Conditioning

    Article • Biology of Blood and Marrow Transplantation, March 2015, Elsevier

    Dr David Gomez-Almaguer, Rosario Salazar Riojas

  24. Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience

    Article • Leukemia & Lymphoma, February 2015, Taylor & Francis

    Dr David Gomez-Almaguer

  25. Health-Related Quality of Life in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation Employing the Mexican Reduced-Intensity Conditioning

    Article • Biology of Blood and Marrow Transplantation, February 2015, Elsevier

    Dr David Gomez-Almaguer

  26. Reduced-Intensity Stem Cell Allografting for PNH Patients in the Eculizumab Era: The Mexican Experience

    Article • Biology of Blood and Marrow Transplantation, February 2015, Elsevier

    Dr David Gomez-Almaguer

  27. Identification of Differentially Expressed Genes Associated with Prognosis of B Acute Lymphoblastic Leukemia

    Article • Disease Markers, January 2015, Hindawi Publishing Corporation

    Dr David Gomez-Almaguer

  28. Effective collection of peripheral blood stem cells in children weighing 20 kilogram or less in a single large-volume apheresis procedure

    Article • Journal of Clinical Apheresis, December 2014, Wiley

    Dr David Gomez-Almaguer

  29. Matched sibling donors versus alternative donors in allogeneic hematopoietic stem cell transplantation for pediatric severe aplastic anemia in México

    Article • Hematology, December 2014, Taylor & Francis

    Dr David Gomez-Almaguer

  30. Safety and Cost-Effectiveness of a Simplified Method for Lumbar Puncture in Patients with Hematologic Malignancies

    Article • Acta Haematologica, October 2014, Karger Publishers

    Dr David Gomez-Almaguer

  31. Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience

    Article • Hematology, August 2014, Taylor & Francis

    Professor Guillermo Jose Ruiz-Arguelles, Dr David Gomez-Almaguer

  32. Cultural factors related to adherence to imatinib in CML: A Mexican perspective

    Article • Hematology, July 2014, Taylor & Francis

    Dr David Gomez-Almaguer

  33. Chemotherapy Alone or HSCT After Reduced-Intensity Conditioning for Patients with Malignant Hematologic Diseases Are Not Associated to Metabolic Syndrome: A Cross-Sectional Observational Study

    Article • Nutrition and Cancer, June 2014, Taylor & Francis

    Dr David Gomez-Almaguer

  34. Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial

    Article • Cytotherapy, June 2014, Elsevier

    Dr David Gomez-Almaguer, Rosario Salazar Riojas

  35. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

    Article • Blood, May 2014, American Society of Hematology

    Dr David Gomez-Almaguer

  36. Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction

    Article • Hematology, February 2014, Taylor & Francis

    Professor Guillermo Jose Ruiz-Arguelles, Dr David Gomez-Almaguer

  37. Subsequent Malignant Neoplasms after Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and Outpatient Conduction

    Article • Biology of Blood and Marrow Transplantation, February 2014, Elsevier

    Dr David Gomez-Almaguer

  38. Characteristics and Clinical Evolution of Patients with Acute Myeloblastic Leukemia in Northeast Mexico: An Eight-Year Experience at a University Hospital

    Article • Acta Haematologica, January 2014, Karger Publishers

    Dr David Gomez-Almaguer

  39. Feasibility of an outpatient HLA haploidentical stem cell transplantation program in children using a reduced-intensity conditioning regimen and CD3–CD19 depletion

    Article • Hematology, November 2013, Taylor & Francis

    Dr David Gomez-Almaguer

  40. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?

    Article • Transfusion, October 2013, Wiley

    Dr David Gomez-Almaguer

  41. A Multicenter, Open-Label, Noncomparative Screening Study of Enzastaurin in Adult Patients With Non-Hodgkin Lymphomas

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2013, Elsevier

    Dr David Gomez-Almaguer

  42. Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia

    Article • Hematology, July 2013, Taylor & Francis

    Dr David Gomez-Almaguer

  43. Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: Report of four cases

    Article • Hematology, July 2013, Taylor & Francis

    Dr David Gomez-Almaguer

  44. Obesity is associated with higher overall survival in patients undergoing an outpatient reduced-intensity conditioning hematopoietic stem cell transplant

    Article • Blood Cells Molecules and Diseases, June 2013, Elsevier

    Dr David Gomez-Almaguer

  45. Current Approaches for the Treatment of Autoimmune Hemolytic Anemia

    Article • Archivum Immunologiae et Therapiae Experimentalis, May 2013, Springer Science + Business Media

    Dr David Gomez-Almaguer

  46. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease

    Article • Journal of Clinical Apheresis, May 2013, Wiley

    Dr David Gomez-Almaguer

  47. Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients

    Article • Diabetology & Metabolic Syndrome, April 2013, Springer Science + Business Media

    Dr David Gomez-Almaguer

  48. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia

    Article • European Journal Of Haematology, April 2013, Wiley

    Dr David Gomez-Almaguer

  49. Another Method for Thawing Hematopoietic Stem Cells and its Impact in the Recovery of the Transplanted Hematological Patient

    Article • Biology of Blood and Marrow Transplantation, February 2013, Elsevier

    Dr David Gomez-Almaguer

  50. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL

    Article • Blood, January 2013, American Society of Hematology

    Dr David Gomez-Almaguer

  51. More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia

    Article • Acta Haematologica, January 2013, Karger Publishers

    Dr David Gomez-Almaguer

  52. Acute maternal cytomegalovirus infection is associated with significantly decreased numbers of CD34+ cells in umbilical cord blood

    Article • Blood Cells Molecules and Diseases, October 2012, Elsevier

    Dr David Gomez-Almaguer, Rosario Salazar Riojas

  53. Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin’s lymphoma in a developing country?

    Article • Hematology, July 2012, Taylor & Francis

    Dr David Gomez-Almaguer

  54. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting

    Article • American Journal of Hematology, June 2012, Wiley

    Dr David Gomez-Almaguer

  55. Treatment of hairy cell leukemia: long-term results in a developing country

    Article • Hematology, May 2012, Taylor & Francis

    Professor Guillermo Jose Ruiz-Arguelles, Dr David Gomez-Almaguer

  56. Cord blood banking activities at a university hospital in northeast Mexico: an 8‐year experience

    Article • Transfusion, April 2012, Wiley

    Dr David Gomez-Almaguer, José C Jaime-Pérez

  57. Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation

    Article • Hematology, March 2012, Taylor & Francis

    Professor Guillermo Jose Ruiz-Arguelles, Dr David Gomez-Almaguer

  58. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value

    Article • Hematology, March 2012, Taylor & Francis

    Dr David Gomez-Almaguer

  59. Antibodies in the Treatment of Aplastic Anemia

    Article • Archivum Immunologiae et Therapiae Experimentalis, February 2012, Springer Science + Business Media

    Dr David Gomez-Almaguer

  60. Therapy of Steroid-Refractory Chronic GVHD with Subcutaneous Low-Dose Alemtuzumab and Rituximab Combination Is Effective and Safe

    Article • Biology of Blood and Marrow Transplantation, February 2012, Elsevier

    Dr David Gomez-Almaguer

  61. Outpatient Stem Cell Transplantation Using a Reduced-Intensity Conditioning in Type 1 Diabetes Mellitus

    Article • Biology of Blood and Marrow Transplantation, February 2012, Elsevier

    Dr David Gomez-Almaguer

  62. Trends in Utilization of Total Body Irradiation (TBI) Prior to Hematopoietic Cell Transplantation (HCT) Worldwide

    Article • Biology of Blood and Marrow Transplantation, February 2012, Elsevier

    Dr David Gomez-Almaguer

  63. Radiotherapeutic Techniques in Allogeneic Hematopoietic Cell Transplant (HCT)

    Article • Biology of Blood and Marrow Transplantation, February 2012, Elsevier

    Dr David Gomez-Almaguer

  64. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP)

    Article • Hematology, January 2012, Taylor & Francis

    Dr David Gomez-Almaguer

  65. Use of complementary and alternative medicine by patients with hematological diseases: experience at a university hospital in northeast Mexico

    Article • Revista Brasileira de Hematologia e Hemoterapia, January 2012, Revista Brasileira de Hematologia e Hemoterapia (RBHH)

    Dr David Gomez-Almaguer

  66. Acute lymphoblastic leukemia of childhood presenting as aplastic anemia: report of two cases

    Article • Revista Brasileira de Hematologia e Hemoterapia, January 2012, Revista Brasileira de Hematologia e Hemoterapia (RBHH)

    Dr David Gomez-Almaguer

  67. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease

    Article • Haematologica, December 2011, Ferrata Storti Foundation (Haematologica)

    Dr David Gomez-Almaguer

  68. Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning

    Article • European Journal Of Haematology, November 2011, Wiley

    Dr David Gomez-Almaguer

  69. Skin Manifestations Associated with Chemotherapy in Children with Hematologic Malignancies

    Article • Pediatric Dermatology, November 2011, Wiley

    Dr David Gomez-Almaguer

  70. Autologous stem cells for the treatment of post-mastectomy lymphedema: a pilot study

    Article • Cytotherapy, November 2011, Elsevier

    Dr David Gomez-Almaguer

  71. TP2 Patrones De Tratamiento De La Leucemia Mieloide Crónica (Lmc) En Pacientes Resistentes O Intolerantes A Imatinib En Instituciones De Salud Pública En México

    Article • Value in Health, November 2011, Elsevier

    Dr David Gomez-Almaguer

  72. Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters: A Receiver Operating Characteristic Curve Modeling Approach

    Article • American Journal of Clinical Pathology, October 2011, Oxford University Press (OUP)

    Dr David Gomez-Almaguer

  73. Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country

    Article • Hematology, May 2011, Taylor & Francis

    Dr David Gomez-Almaguer

  74. Reduced-Intensity Allografting in Childhood Acute Lymphoblastic Leukemia

    Article • Biology of Blood and Marrow Transplantation, March 2011, Elsevier

    Dr David Gomez-Almaguer

  75. Outpatient HLA-Haploidentical Stem Cell Transplantation in Children Using a Reduced-Intensity Conditioning Regimen and CD3-CD19 Depletion

    Article • Biology of Blood and Marrow Transplantation, February 2011, Elsevier

    Dr David Gomez-Almaguer

  76. Intrathecal Autologous Total Nucleated Cells for Children With Hipoxic/Ischemic Brain Injury

    Article • Biology of Blood and Marrow Transplantation, February 2011, Elsevier

    Dr David Gomez-Almaguer

  77. Danazol as first-line therapy for aplastic anemia

    Article • Annals of Hematology, January 2011, Springer Science + Business Media

    Dr David Gomez-Almaguer

  78. Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia?

    Article • Pediatric Blood & Cancer, January 2011, Wiley

    Dr David Gomez-Almaguer

  79. PSY24 COST OF CARE FOR CHRONIC MYELOID LEUKEMIA (CML) IN PATIENTS EXPERIENCING RESISTANCE AND/OR INTOLERANCE TO IMATINIB FROM THE PUBLIC HEALTH SYSTEM PERSPECTIVE IN MEXICO

    Article • Value in Health, November 2010, Elsevier

    Dr David Gomez-Almaguer

  80. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias

    Article • Blood, September 2010, American Society of Hematology

    Dr David Gomez-Almaguer

  81. Outpatient reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia in children

    Article • British Journal of Haematology, August 2010, Wiley

    Dr David Gomez-Almaguer

  82. Pediatric hematopoietic SCT in Mexico: recent activity and main problems

    Article • Bone Marrow Transplantation, June 2010, Nature

    Dr David Gomez-Almaguer

  83. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method

    Article • Annals of Hematology, May 2010, Springer Science + Business Media

    Dr David Gomez-Almaguer

  84. CD133+ cell content does not influence recovery time after hematopoietic stem cell transplantation

    Article • Transfusion, November 2009, Wiley

    Dr David Gomez-Almaguer

  85. Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia

    Article • Leukemia & Lymphoma, October 2009, Taylor & Francis

    Dr David Gomez-Almaguer

  86. Molecular characterization of chronic myeloproliferative neoplasias in México

    Article • Hematology, October 2009, Taylor & Francis

    Dr David Gomez-Almaguer

  87. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia

    Article • Annals of Hematology, August 2009, Springer Science + Business Media

    Dr David Gomez-Almaguer

  88. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study

    Article • European Journal Of Haematology, April 2009, Wiley

    Dr David Gomez-Almaguer

  89. Mobilization kinetics of CD133+ hematoprogenitor cells for hematopoietic grafting

    Article • Transfusion, March 2009, Wiley

    Dr David Gomez-Almaguer

  90. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy

    Article • British Journal of Haematology, March 2009, Wiley

    Dr David Gomez-Almaguer

  91. Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria

    Article • Hematology, February 2009, Taylor & Francis

    Dr David Gomez-Almaguer

  92. A Single Apheresis Procedure in the Donor May Be Enough to Complete an Allograft Using the “Mexican Method” of Non-Ablative Allografting

    Article • Biology of Blood and Marrow Transplantation, February 2009, Elsevier

    Dr David Gomez-Almaguer

  93. Reduced-Intensity Allogeneic Versus Autologous Peripheral Blood Stem Cell Transplantation In Patients With Hodgkin's and Non-Hodgkin's Lymphoma

    Article • Biology of Blood and Marrow Transplantation, February 2009, Elsevier

    Dr David Gomez-Almaguer

  94. Dimethyl Sulfoxide-Induced Toxicity in Cord Blood Stem Cell Transplantation: Report of Three Cases and Review of the Literature

    Article • Acta Haematologica, January 2009, Karger Publishers

    Dr David Gomez-Almaguer

  95. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

    Article • Bone Marrow Transplantation, July 2008, Nature

    Dr David Gomez-Almaguer

  96. Making Allogeneic Bone Marrow Transplantation Available to Patients in Developing Countries: The Mexican Experience

    Article • The Open Hematology Journal, May 2008, Bentham Science Publishers

    Dr David Gomez-Almaguer

  97. 157: Therapeutic Choices in Patients with Ph1 (+) Chronic Myelogenous Leukemia Living in Developing Countries in the Tyrosine Kinase Inhibitors (TKI) Era: Stem Cell Transplantation or TKI?

    Article • Biology of Blood and Marrow Transplantation, February 2008, Elsevier

    Dr David Gomez-Almaguer

  98. Alemtuzumab for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

    Article • Biology of Blood and Marrow Transplantation, January 2008, Elsevier

    Dr David Gomez-Almaguer

  99. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING A REDUCED-INTENSITY CONDITIONING REGIMEN IN INFANTS: EXPERIENCE AT A SINGLE INSTITUTION IN MEXICO

    Article • Pediatric Hematology and Oncology, January 2008, Taylor & Francis

    Dr David Gomez-Almaguer

  100. Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study

    Article • Bone Marrow Transplantation, July 2007, Nature

    Dr David Gomez-Almaguer

  101. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience

    Article • Hematology, June 2007, Taylor & Francis

    Dr David Gomez-Almaguer

  102. Outpatient allografting using non-myeloablative conditioning: the Mexican experience

    Article • Bone Marrow Transplantation, May 2007, Nature

    Dr David Gomez-Almaguer

  103. 240: Reduced-intensity stem cell transplantation in patients with high-risk acute lymphoblastic leukemia (ALL)

    Article • Biology of Blood and Marrow Transplantation, February 2007, Elsevier

    Dr David Gomez-Almaguer

  104. 268: Umbilical cord blood transplantation using non-myeloablative conditioning

    Article • Biology of Blood and Marrow Transplantation, February 2007, Elsevier

    Dr David Gomez-Almaguer

  105. 294: Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease

    Article • Biology of Blood and Marrow Transplantation, February 2007, Elsevier

    Dr David Gomez-Almaguer

  106. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan

    Article • Annals of Hematology, January 2007, Springer Science + Business Media

    Dr David Gomez-Almaguer

  107. Assessment of nutritional status in children with acute lymphoblastic leukemia in Northern México: A 5-year experience

    Article • Pediatric Blood & Cancer, January 2007, Wiley

    Dr David Gomez-Almaguer

  108. Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen

    Article • European Journal Of Haematology, October 2006, Wiley

    Dr David Gomez-Almaguer

  109. Umbilical cord blood transplantation using non-myeloablative conditioning: The Mexican experience

    Article • Hematology, October 2006, Taylor & Francis

    Dr David Gomez-Almaguer

  110. Nephrotic syndrome after non-myeloablative stem cell transplantation

    Article • British Journal of Haematology, March 2006, Wiley

    Dr David Gomez-Almaguer

  111. Autologous peripheral blood stem cell transplantation in multiple myeloma using melphalan: The Mexican experience

    Article • Biology of Blood and Marrow Transplantation, February 2006, Elsevier

    Dr David Gomez-Almaguer

  112. Allogeneic stem cell transplantation in infants. A single institution experience

    Article • Biology of Blood and Marrow Transplantation, February 2006, Elsevier

    Dr David Gomez-Almaguer

  113. The early referral for reduced-intensity stem cell transplantation in patients with ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicen...

    Article • Biology of Blood and Marrow Transplantation, February 2006, Elsevier

    Dr David Gomez-Almaguer

  114. Transient mixed chimerism after stem cell transplantation can induce durable molecular complete remissions in chronic myelogenous leukemia

    Article • Leukemia & Lymphoma, January 2006, Taylor & Francis

    Dr David Gomez-Almaguer

  115. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience

    Article • American Journal of Hematology, January 2006, Wiley

    Dr David Gomez-Almaguer

  116. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicen...

    Article • Bone Marrow Transplantation, October 2005, Nature

    Dr David Gomez-Almaguer

  117. Extramedullary Leukemic Relapses following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning

    Article • International Journal of Hematology, October 2005, Springer Science + Business Media

    Dr David Gomez-Almaguer

  118. Sub-Optimal Fetal Iron Acquisition under a Maternal Environment

    Article • Archives of Medical Research, September 2005, Elsevier

    Dr David Gomez-Almaguer

  119. Haematopoietic stem cell transplantation to treat aplastic anaemia

    Article • Expert Opinion on Biological Therapy, May 2005, Informa Healthcare

    Dr David Gomez-Almaguer

  120. Platelet refractoriness to classical agonists in a child with essential thrombocythemia

    Article • Platelets, February 2005, Taylor & Francis

    Dr David Gomez-Almaguer

  121. Gilbert's syndrome disclosed during the treatment of hematological malignancies

    Article • Hematology, February 2005, Taylor & Francis

    Dr David Gomez-Almaguer

  122. Choosing the patient for ambulatory stem cell transplantation

    Article • Biology of Blood and Marrow Transplantation, February 2005, Elsevier

    Dr David Gomez-Almaguer, Rosario Salazar Riojas

  123. Non-myeloablative conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. The impact of the remission status

    Article • Biology of Blood and Marrow Transplantation, February 2005, Elsevier

    Dr David Gomez-Almaguer, Rosario Salazar Riojas

  124. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience

    Article • Biology of Blood and Marrow Transplantation, February 2005, Elsevier

    Dr David Gomez-Almaguer

  125. Breaking dogmata to help patients: non-myeloablative haematopoietic stem cell transplantation

    Article • Expert Opinion on Biological Therapy, October 2004, Informa Healthcare

    Dr David Gomez-Almaguer

  126. Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning in Patients with Acute Myelogenous Leukemia Eligible for Conventional Allografting: A Prospective Study

    Article • Leukemia & Lymphoma, June 2004, Taylor & Francis

    Dr David Gomez-Almaguer

  127. Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy

    Article • Archives of Medical Research, March 2004, Elsevier

    Dr David Gomez-Almaguer

  128. Patients with severe aplastic anemia can be allografted succesfully without anti-thymocyte globulin, using a non-myeloablative conditioning regimen

    Article • Biology of Blood and Marrow Transplantation, February 2004, Elsevier

    Dr David Gomez-Almaguer

  129. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: results of a prospective, multicenter study

    Article • Biology of Blood and Marrow Transplantation, February 2004, Elsevier

    Dr David Gomez-Almaguer

  130. Fludarabine and Once-Daily Intravenous Busulfan for Allogeneic Bone Marrow Transplantation for Chediak-Higashi Syndrome

    Article • Journal of Pediatric Hematology/Oncology, October 2003, Wolters Kluwer Health

    Dr David Gomez-Almaguer

  131. The Mexican Approach to Conduct Nonmyeloablative Stem Cell Transplantation Should Not Be Overlooked

    Article • International Journal of Hematology, June 2003, Springer Science + Business Media

    Dr David Gomez-Almaguer

  132. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience

    Article • Biology of Blood and Marrow Transplantation, March 2003, Elsevier

    Dr David Gomez-Almaguer

  133. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience

    Article • Biology of Blood and Marrow Transplantation, March 2003, Elsevier

    Dr David Gomez-Almaguer

  134. Role of bone marrow examination in staging Hodgkin's disease: experience in México

    Article • International Journal of Laboratory Hematology, August 2002, Wiley

    Dr David Gomez-Almaguer

  135. Iron Stores in Low-Income Pregnant Mexican Women at Term

    Article • Archives of Medical Research, January 2002, Elsevier

    Dr David Gomez-Almaguer

  136. The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients

    Article • International Journal of Hematology, January 2002, Springer Science + Business Media

    Dr David Gomez-Almaguer

  137. No Cytomegalovirus-related Deaths After Non-ablative Stem Cell Allografts

    Article • Hematology, January 2002, Taylor & Francis

    Dr David Gomez-Almaguer

  138. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens

    Article • American Journal of Hematology, March 2001, Wiley

    Dr David Gomez-Almaguer

  139. Features of the Engraftment of Allogeneic Hematopoietic Stem Cells Using Reduced-Intensity Conditioning Regimens

    Article • Leukemia & Lymphoma, January 2001, Taylor & Francis

    Dr David Gomez-Almaguer

  140. High‐dose cyclophosphamide in the treatment of severe aplastic anemia in children

    Article • American Journal of Hematology, January 2001, Wiley

    Dr David Gomez-Almaguer

  141. Immunoreactivity of Common Red Blood Cell Antigens in Cytoskeleton-Free Red Blood Cell Microvesicles

    Article • Archives of Medical Research, March 2000, Elsevier

    Dr David Gomez-Almaguer

  142. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases

    Article • Bone Marrow Transplantation, February 2000, Nature

    Dr David Gomez-Almaguer

  143. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children

    Article • American Journal of Hematology, January 2000, Wiley

    Dr David Gomez-Almaguer

  144. All trans‐retinoic acid decreases early mortality in patients with promyelocytic leukemia and can be given entirely on an outpatient basis

    Article • American Journal of Hematology, November 1999, Wiley

    Dr David Gomez-Almaguer

  145. Alltrans-retinoic acid decreases early mortality in patients with promyelocytic leukemia and can be given entirely on an outpatient basis

    Article • American Journal of Hematology, November 1999, Wiley

    Dr David Gomez-Almaguer

  146. High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen

    Article • Bone Marrow Transplantation, October 1999, Nature

    Dr David Gomez-Almaguer

  147. Bone Marrow Transplantation in a Child with Hemophagocytic Lymphohistiocytosis Using a Less Toxic Conditioning Regimen

    Article • Archives of Medical Research, July 1999, Elsevier

    Dr David Gomez-Almaguer

  148. Detecting residual bcr-abl transcripts in chronic myeloid leukaemia patients using coupled reverse transcriptase-polymerase chain reaction with rTth DNA polymerase

    Article • International Journal of Laboratory Hematology, August 1998, Wiley

    Dr David Gomez-Almaguer

  149. Hairy cell leukemia is infrequent in México and has a geographic distribution

    Article • American Journal of Hematology, August 1996, Wiley

    Dr David Gomez-Almaguer

  150. Hairy cell leukemia is infrequent in México and has a geographic distribution

    Article • American Journal of Hematology, August 1996, Wiley

    Dr David Gomez-Almaguer

  151. Dexamethasone in the treatment of meningeal leukemia

    Article • American Journal of Hematology, August 1995, Wiley

    Dr David Gomez-Almaguer

  152. Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study

    Article • British Journal of Haematology, December 1992, Wiley

    Dr David Gomez-Almaguer

  153. Authors' reply

    Article • American Journal of Hematology, July 1989, Wiley

    Dr David Gomez-Almaguer

  154. Vasculitis in hairy cell leukemia: Rapid response to interferon alpha

    Article • American Journal of Hematology, April 1989, Wiley

    Dr David Gomez-Almaguer

  155. Acyclovir in the treatment of aplastic anemia

    Article • American Journal of Hematology, November 1988, Wiley

    Dr David Gomez-Almaguer